YieldMax MRNA Option Income Strategy ETF Stock to Reverse Split on Monday, December 1st (NYSEARCA:MRNY)

Posted by Francis Steltz on Nov 19th, 2025

YieldMax MRNA Option Income Strategy ETF (NYSEARCA:MRNY – Free Report)’s stock is scheduled to reverse split on Monday, December 1st. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, November 30th.

YieldMax MRNA Option Income Strategy ETF Trading Up 0.7%

Shares of NYSEARCA MRNY opened at $1.52 on Wednesday. The business’s fifty day simple moving average is $1.68 and its 200-day simple moving average is $2.07. YieldMax MRNA Option Income Strategy ETF has a 12-month low of $1.46 and a 12-month high of $5.77.

YieldMax MRNA Option Income Strategy ETF Dividend Announcement

The business also recently declared a dividend, which was paid on Friday, November 14th. Shareholders of record on Thursday, November 13th were issued a dividend of $0.0221 per share. The ex-dividend date was Thursday, November 13th. This represents a yield of 8,885.0%.

Hedge Funds Weigh In On YieldMax MRNA Option Income Strategy ETF

An institutional investor recently raised its position in YieldMax MRNA Option Income Strategy ETF stock. OLD Mission Capital LLC boosted its position in YieldMax MRNA Option Income Strategy ETF (NYSEARCA:MRNY – Free Report) by 235.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 99,034 shares of the company’s stock after acquiring an additional 69,476 shares during the quarter. OLD Mission Capital LLC owned 0.34% of YieldMax MRNA Option Income Strategy ETF worth $273,000 at the end of the most recent quarter.

YieldMax MRNA Option Income Strategy ETF Company Profile

(Get Free Report)

The YieldMax MRNA Option Income Strategy ETF (MRNY) is an exchange-traded fund that mostly invests in health care equity. The fund seeks to provide current income and capped gains on the Moderna stock (MRNA) through a synthetic covered call strategy, collateralized by cash and US Treasurys. The actively managed fund uses both standardized exchange-traded and FLEX options.